Trends in hospitalizations of pregnant HIV-infected women in the United States: 2004 through 2011

American Journal of Obstetrics and Gynecology

Volumn 215, Issue 4, 2016, Pages 499.e1-499.e8

  Ewing, Alexander C ^a   Datwani, Hema M ^a   Flowers, Lisa M ^a   Ellington, Sascha R ^a   Jamieson, Denise J ^a   Kourtis, Athena P ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

delivery; HIV; hospitalization; pregnancy; United States

Indexed keywords

ADOLESCENT; ADULT; ADVERSE OUTCOME; ANTEPARTUM HEMORRHAGE; BACTERIAL INFECTION; CONFERENCE PAPER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HOSPITAL CHARGE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; LENGTH OF STAY; LIVER DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; MYCOSIS; PARASITOSIS; PELVIC INFLAMMATORY DISEASE; POPULATION RESEARCH; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PUERPERAL INFECTION; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; URINARY TRACT INFECTION; BACTERIAL INFECTIONS; COMPLICATION; DIABETES, GESTATIONAL; HIV INFECTIONS; HYPERTENSION, PREGNANCY-INDUCED; MIDDLE AGED; ODDS RATIO; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY COMPLICATIONS, INFECTIOUS; STATISTICS AND NUMERICAL DATA; TRENDS; YOUNG ADULT;

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; BACTERIAL INFECTIONS; CROSS-SECTIONAL STUDIES; DIABETES, GESTATIONAL; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MIDDLE AGED; ODDS RATIO; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84978484044     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.05.048     Document Type: Conference Paper

References (59)

1. 1 Siegfried, N., van der Merwe, L., Brocklehurst, P., Sint, T.T., Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev(7), 2011, CD003510.
2. 2 Fowler, M.G., Gable, A.R., Lampe, M.A., Etima, M., Owor, M., Perinatal HIV and its prevention: progress toward an HIV-free generation. Clin Perinatol 37 (2010), 699–719 vii.
3. 3 National Institutes of Health. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. 2014:C-25. Accessed July 10, 2015.
4. 4 Mandelbrot, L., Landreau-Mascaro, A., Rekacewicz, C., et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 285 (2001), 2083–2093.
5. 5 Mofenson, L.M., US Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 51 (2002), 1–38.
6. 6 Steiner, R.J., Finocchario-Kessler, S., Dariotis, J.K., Engaging HIV care providers in conversations with their reproductive-age patients about fertility desires and intentions: a historical review of the HIV epidemic in the United States. Am J Public Health 103 (2013), 1357–1366.
7. 7 Samji, H., Cescon, A., Hogg, R.S., et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One, 8, 2013, e81355.
8. 8 Justice, A.C., HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 7 (2010), 69–76.
9. 9 Whitmore, S.K., Zhang, X., Taylor, A.W., Blair, J.M., Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr 57 (2011), 218–222.
10. 10 Watts, D.H., Balasubramanian, R., Maupin, R.T. Jr., et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 190 (2004), 506–516.
11. 11 Gonzalez-Tome, M.I., Ramos Amador, J.T., Guillen, S., et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med 9 (2008), 868–874.
12. 12 Ouyang, D.W., Shapiro, D.E., Lu, M., et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS 23 (2009), 2425–2430.
13. 13 Sturt, A.S., Dokubo, E.K., Sint, T.T., Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev, 2010, CD008440.
14. 14 Chougrani, I., Luton, D., Matheron, S., Mandelbrot, L., Azria, E., Safety of protease inhibitors in HIV-infected pregnant women. HIV AIDS (Auckl) 5 (2013), 253–262.
15. 15 Huntington, S., Thorne, C., Newell, M.-L., et al. Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. AIDS 29 (2015), 801–809.
16. 16 Ouyang, D.W., Brogly, S.B., Lu, M., et al. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS 24 (2010), 109–114.
17. 17 Hitti, J., Andersen, J., McComsey, G., et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 196 (2007), 331.e1–331.e7.
18. 18 Wimalasundera, R.C., Larbalestier, N., Smith, J.H., et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 360 (2002), 1152–1154.
19. 19 Suy, A., Martinez, E., Coll, O., et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 20 (2006), 59–66.
20. 20 Machado, E.S., Krauss, M.R., Megazzini, K., et al. Hypertension, preeclampsia and eclampsia among HIV-infected pregnant women from Latin America and Caribbean countries. J Infect 68 (2014), 572–580.
21. 21 Lorenzi, P., Spicher, V.M., Laubereau, B., et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 12 (1998), F241–F247.
22. 22 Tuomala, R.E., Shapiro, D.E., Mofenson, L.M., et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 346 (2002), 1863–1870.
23. 23 Schulte, J., Dominguez, K., Sukalac, T., Bohannon, B., Fowler, M.G., Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics 119 (2007), e900–e906.
24. 24 Martin, F., Taylor, G.P., Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: a single-center cohort study. J Infect Dis 196 (2007), 558–561.
25. 25 Kourtis, A.P., Schmid, C.H., Jamieson, D.J., Lau, J., Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 21 (2007), 607–615.
26. 26 Townsend, C., Schulte, J., Thorne, C., et al. Antiretroviral therapy and preterm delivery–a pooled analysis of data from the United States and Europe. BJOG 117 (2010), 1399–1410.
27. 27 Rudin, C., Spaenhauer, A., Keiser, O., et al. Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. HIV Med 12 (2011), 228–235.
28. 28 Powis, K.M., Kitch, D., Ogwu, A., et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 204 (2011), 506–514.
29. 29 Sibiude, J., Warszawski, J., Tubiana, R., et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?. Clin Infect Dis 54 (2012), 1348–1360.
30. 30 Lopez, M., Figueras, F., Hernandez, S., et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. AIDS 26 (2012), 37–43.
31. 31 Kourtis, A.P., Bansil, P., McPheeters, M., Meikle, S.F., Posner, S.F., Jamieson, D.J., Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART, 1994-2003. AIDS 20 (2006), 1823–1831.
32. 32 Healthcare Cost and Utilization Project. National (Nationwide) Inpatient Sample overview. The National (Nationwide) Inpatient Sample database documentation, 2014. Available at: http://www.hcup-us.ahrq.gov/nisoverview.jsp#multi. Accessed March 9, 2015.
33. 33 Steiner, C., Elixhauser, A., Schnaier, J., The healthcare cost and utilization project: an overview. Eff Clin Pract 5 (2002), 143–151.
34. 34 Agency for Healthcare Research and Quality. 2004 NIS design report. The National (Nationwide) Inpatient Sample database documentation, 2011. Available at: www.hcup-us.ahrq.gov/db/nation/nis/reports/NIS_2004_Design_Report.jsp. Accessed March 9, 2015.
35. 35 Houchens, R., Elixhauser, A., Using the HCUP Nationwide Inpatient Sample to estimate trends. 2006, US Agency for Healthcare Research and Quality, Rockville, MD.
36. 36 Gillum, B.S., Graves, E.J., Jean, L., Trends in hospital utilization: United States, 1988-92. Vital Health Stat 13, 1996, 1–71.
37. 37 Centers for Disease Control and Prevention (CDC). Achievements in public health. Reduction in perinatal transmission of HIV infection–United States, 1985-2005. MMWR 55 (2006), 592–597.
38. 38 Pazol, K., Creanga, A.A., Jamieson, D.J., Abortion surveillance–United States, 2012. MMWR 64:No. SS-10 (2015), 1–40.
39. 39 Rahangdale, L., Stewart, A., Stewart, R.D., et al. Pregnancy intentions among women living with HIV in the United States. J Acquir Immune Defic Syndr 65 (2014), 306–311.
40. 40 Sutton, M.Y., Patel, R., Frazier, E.L., Unplanned pregnancies among HIV-infected women in care–United States. J Acquir Immune Defic Syndr 65 (2014), 350–358.
41. 41 Sun, M., Peipert, J.F., Zhao, Q., et al. Trends in contraceptive use among women with human immunodeficiency virus. Obstet Gynecol 120 (2012), 783–790.
42. 42 Chu, S.Y., Callaghan, W.M., Kim, S.Y., et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care 30 (2007), 2070–2076.
43. 43 Dekker, G., Sibai, B., Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 357 (2001), 209–215.
44. 44 American College of Obstetricians and Gynecologists. Obesity in pregnancy. ACOG practice bulletin no. 156. Obstet Gynecol 126 (2015), e112–e126.
45. 45 Albrecht, S.S., Kuklina, E.V., Bansil, P., et al. Diabetes trends among delivery hospitalizations in the US, 1994–2004. Diabetes Care 33 (2010), 768–773.
46. 46 Martin, J.A., Hamilton, B.E., Osterman, M.J.K., Curtin, S.C., Mathews, T.J., Births: final data for 2013. Natl Vital Stat Rep 64 (2015), 1–65.
47. 47 International Association of Diabetes and Pregnancy Study Groups. Recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33 (2010), 676–682.
48. 48 Metzger, B.E., Buchanan, T.A., Coustan, D.R., et al. Summary and recommendations of the fifth international workshop-conference on gestational diabetes mellitus. Diabetes Care 30:Suppl (2007), S251–S260.
49. 49 Perinatal HIV Guidelines Working Group. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2009:13-38. Available at: https://aidsinfo.nih.gov/contentfiles/perinatalgl02112007901.pdf. Accessed July 15, 2015.
50. 50 National Institutes of Health. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. 2004:15-24. Available at: https://aidsinfo.nih.gov/contentfiles/adultandadolescentgl000721.pdf. Accessed July 15, 2015.
51. 51 National Institutes of Health. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. 2007:12-23, 44-46. Available at: https://aidsinfo.nih.gov/contentfiles/adultandadolescentgl000721.pdf. Accessed July 15, 2015.
52. 52 National Institutes of Health. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. 2009:22-80, 95-99. Available at: https://aidsinfo.nih.gov/contentfiles/adultandadolescentgl001561.pdf. Accessed July 15, 2015.
53. 53 Boyd, S.D., Management of HIV infection in treatment-naive patients: a review of the most current recommendations. Am J Health Syst Pharm 68 (2011), 991–1001.
54. 54 Cantwell, R., Clutton-Brock, T., Cooper, G., et al. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG 118:Suppl (2011), 1–203.
55. 55 Bauer, M.E., Bateman, B.T., Bauer, S.T., Shanks, A.M., Mhyre, J.M., Maternal sepsis mortality and morbidity during hospitalization for delivery: temporal trends and independent associations for severe sepsis. Anesth Analg 117 (2013), 944–950.
56. 56 Centers for Disease Control and Prevention. HIV surveillance report, 2014; vol. 26. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed April 2, 2016.
57. 57 Martin, J.A., Hamilton, B.E., Ventura, S.J., Osterman, M.J., Mathews, T., Births: final data for 2011. Natl Vital Stat Rep 62 (2013), 1–90.
58. 58 Creanga, A.A., Berg, C.J., Ko, J.Y., et al. Maternal mortality and morbidity in the United States: where are we now?. J Womens Health (Larchmt) 23 (2014), 3–9.
59. 59 Howell, E.A., Egorova, N., Balbierz, A., Zeitlin, J., Hebert, P.L., Black-white differences in severe maternal morbidity and site of care. Am J Obstet Gynecol 214 (2016), 122.e1–122.e7.